                         SEQUENCE LISTING

<110>  Regeneron Pharmaceuticals, Inc.
       HUANG, Ming
       QIU, Haibo
       XU, Xiaobin
       LI, Ning
 
<120>  USE OF LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY TO 
       CHARACTERIZE OLIGONUCLEOTIDES

<130>  REGE-020/001WO 181937-2305

<150>  62/968,368
<151>  2020-01-31

<160>  18    

<170>  PatentIn version 3.5

<210>  1
<211>  17
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  M13 Reverse oligo

<400>  1
caggaaacag ctatgac                                                      17


<210>  2
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TRC-F oligo

<400>  2
caaggctgtt agagagataa ttgga                                             25


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  T7 Oligo

<400>  3
taatacgact cactataggg                                                   20


<210>  4
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  unmodified Oblimersen

<400>  4
tctcccagcg tgcgccat                                                     18


<210>  5
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  oblimersen oligo with modifications


<220>
<221>  phosphorothioate
<222>  (2)..(18)
<223>  * indicates a phosphorothioate linkage

<400>  5
tctcccagcg tgcgccat                                                     18


<210>  6
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SP6 oligo

<400>  6
atttaggtga cactatag                                                     18


<210>  7
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  T3 oligo

<400>  7
gcaattaacc ctcactaaag g                                                 21


<210>  8
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  CMV forward primer

<400>  8
cgcaaatggg cggtaggcgt g                                                 21


<210>  9
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Formivirsen oligo


<220>
<221>  phosphorothioate
<222>  (2)..(21)
<223>  * indicates phosphorothioate linkage

<400>  9
gcgtttgctc ttcttcttgc g                                                 21


<210>  10
<211>  15
<212>  DNA
<213>  Artificial sequence

<220>
<223>  polyT nucleotide

<400>  10
tttttttttt ttttt                                                        15


<210>  11
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  poly(T) oligo

<400>  11
tttttttttt tttttttttt                                                   20


<210>  12
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  poly(T) oligo

<400>  12
tttttttttt tttttttttt ttttt                                             25


<210>  13
<211>  30
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  poly(T) oligo

<400>  13
tttttttttt tttttttttt tttttttttt                                        30


<210>  14
<211>  35
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  poly(T) oligo

<400>  14
tttttttttt tttttttttt tttttttttt ttttt                                  35


<210>  15
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nusinersen oligo


<220>
<221>  MOEr
<222>  (1)..(18)
<223>  2'-O-methoxy-ethyl (MOEr) modification

<220>
<221>  5me
<222>  (2)..(2)
<223>  5-methyl modification

<220>
<221>  *
<222>  (2)..(18)
<223>  * indicates phosphorothioate linkage

<220>
<221>  5me
<222>  (4)..(4)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (8)..(8)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (15)..(15)
<223>  5-methyl modification

<400>  15
tcactttcat aatgctgg                                                     18


<210>  16
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Inotersen


<220>
<221>  MOEr
<222>  (1)..(5)
<223>  2'-O-methoxy-ethyl (MOEr) modification

<220>
<221>  *
<222>  (2)..(20)
<223>  * indicates phosphorothioate linkage

<220>
<221>  5me
<222>  (2)..(2)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (10)..(10)
<223>  5-methyl modification

<220>
<221>  MOEr
<222>  (16)..(20)
<223>  2'-O-methoxy-ethyl (MOEr) modification

<220>
<221>  5me
<222>  (18)..(20)
<223>  5-methyl modification

<400>  16
tcttggttac atgaaatccc                                                   20


<210>  17
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Mipomersen


<220>
<221>  MOEr
<222>  (1)..(5)
<223>  2'-O-methoxy-ethyl (MOEr) modification

<220>
<221>  5me
<222>  (2)..(3)
<223>  5-methyl modification

<220>
<221>  *
<222>  (2)..(20)
<223>  * indicates phosphorothioate linkage

<220>
<221>  5me
<222>  (5)..(5)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (9)..(9)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (12)..(12)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (15)..(15)
<223>  5-methyl modification

<220>
<221>  MOEr
<222>  (16)..(20)
<223>  2'-O-methoxy-ethyl (MOEr) modification

<220>
<221>  5me
<222>  (17)..(17)
<223>  5-methyl modification

<220>
<221>  5me
<222>  (19)..(20)
<223>  5-methyl modification

<400>  17
gcctcagtct gcttcgcacc                                                   20


<210>  18
<211>  16
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  AZD4785


<220>
<221>  cET
<222>  (1)..(3)
<223>  constrained ethyl nucleoside analog

<220>
<221>  *
<222>  (2)..(16)
<223>  * indicates phosphorothioate linkage

<220>
<221>  cET
<222>  (14)..(16)
<223>  constrained ethyl nucleoside analog

<400>  18
gctattagga gtcttt                                                       16


